Lisata Therapeutics, Inc. (LSTA)
(Delayed Data from NSDQ)
$3.41 USD
+0.05 (1.49%)
Updated Jul 10, 2024 04:00 PM ET
After-Market: $3.44 +0.03 (0.88%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth C Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
LSTA 3.41 +0.05(1.49%)
Will LSTA be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for LSTA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LSTA
Lisata's (LSTA) LSTA1 Gets FDA Orphan Drug Tag for Osteosarcoma
Lisata's (LSTA) LSTA1 Gets FDA's RPDD Tag for Osteosarcoma
LSTA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Lisata (LSTA) Stock Up More Than 35% in 3 Months: Here's Why
All You Need to Know About Lisata Therapeutics, Inc. (LSTA) Rating Upgrade to Buy
Lisata's (LSTA) Lead Cancer Drug Gets EC's Orphan Tag, Stock Up
Other News for LSTA
Lisata Therapeutics’ Certepetide Shows Promise in Improving Standard Treatment for Intrahepatic Cholangiocarcinoma in a Preclinical Model
Positive Outlook for Lisata Therapeutics Backed by Clinical Progress and Strategic Partnerships
Analysts Offer Insights on Healthcare Companies: Lisata Therapeutics (LSTA) and Barinthus Biotherapeutics (BRNS)
Analysts Offer Insights on Healthcare Companies: Incyte (INCY) and Lisata Therapeutics (LSTA)
Analysts Conflicted on These Healthcare Names: Incyte (INCY) and Lisata Therapeutics (LSTA)